Genmab A/S (GMAB) Earnings History
Annual and quarterly earnings data from 2002 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 95.4% | 31.1% | 36.4% |
| 2023 | 98.6% | 32.3% | 26.4% |
| 2022 | 100.0% | 43.2% | 37.6% |
| 2021 | 100.0% | 35.1% | 35.1% |
| 2020 | 100.0% | 62.4% | 47.1% |
Download Data
Export GMAB earnings history in CSV or JSON format
Free sign-in required to download data
Genmab A/S (GMAB) Earnings Overview
As of March 1, 2026, Genmab A/S (GMAB) reported trailing twelve-month net income of $6.57B, reflecting +0.8% year-over-year growth. The company earned $10.58 per diluted share over the past four quarters, with a net profit margin of 0.4%.
Looking at the long-term picture, GMAB's 5-year EPS compound annual growth rate (CAGR) stands at +29.0%, indicating exceptional earnings growth. The company achieved its highest annual net income of $7.84B in fiscal 2024, representing a new all-time high.
Genmab A/S maintains positive profitability with a gross margin of 1.0%, operating margin of 0.3%, and net margin of 0.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including RVMD (-$1.13B net income), INCY ($1.29B net income, 0.3% margin), EXEL ($678M net income, 0.3% margin), GMAB has comparable earnings metrics. Compare GMAB vs RVMD →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $7.84B | +80.2% | $6.70B | $12.14 | 36.4% | 31.1% |
| 2023 | $4.35B | -20.2% | $5.32B | $6.60 | 26.4% | 32.3% |
| 2022 | $5.45B | +84.4% | $6.27B | $8.26 | 37.6% | 43.2% |
| 2021 | $2.96B | -37.9% | $2.95B | $4.48 | 35.1% | 35.1% |
| 2020 | $4.76B | +119.7% | $6.31B | $7.22 | 47.1% | 62.4% |
| 2019 | $2.17B | +47.1% | $2.64B | $3.40 | 40.4% | 49.2% |
| 2018 | $1.47B | +33.4% | $1.38B | $2.37 | 48.7% | 45.6% |
| 2017 | $1.10B | -7.0% | $1.34B | $1.78 | 46.7% | 56.8% |
| 2016 | $1.19B | +55.5% | $1.05B | $1.92 | 65.4% | 58.0% |
| 2015 | $764M | +153.4% | $730M | $1.26 | 67.4% | 64.5% |
See GMAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GMAB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GMAB vs AGIO
See how GMAB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GMAB growing earnings?
GMAB EPS of $10.58 reflects slowing growth at +0.8%, below the 5-year CAGR of +29.0%. TTM net income is $6.6B. Expansion rate has moderated.
What are GMAB's profit margins?
Genmab A/S net margin is +0.4%, with operating margin at +0.3%. Below-average margins reflect competitive or cost pressures.
How consistent are GMAB's earnings?
GMAB earnings data spans 2002-2024. The current earnings trend is +0.8% YoY. Historical data enables comparison across business cycles.